HEK293T, HeLa, SKOV3, TOV21G, OVCAR3, OVCAR8, and MCF7 cell lines were purchased from American Type Culture Collection (ATCC). The cell lines were authenticated at ATCC and were used at low (<30) passages. SKOV3 cells were maintained in McCoy’s 5A media, TOV21G cells were cultured in 1:1 mixture of MCDB 105 media and Medium 199, and MCF7 cells were maintained in MEM media with 0.01 mg/ml human recombinant insulin. Other cell lines were maintained in DMEM media and all cell lines were supplemented with 10% FBS and 1% penicillin/streptomycin. The isogenic cell lines (SKOV3 and SKOV3-TR) were obtained from Dr. Michael Seiden (32 (link)). Attractene (Qiagen) was used for transient overexpression following the manufacturer’s instructions. Nocodazole (100 ng/ml for 16–20 h) and Taxol (0.1 μM for 16 h) from LC laboratories were used to arrest cells in mitosis phase unless otherwise indicated. PKR inhibitor imidazole-oxindole C16 was from Sigma. Bcl2-specific inhibitor venetoclax/ABT199 were from AbbVie and Genentech (animal use) and LC Laboratory (for in vitro use). The use of other kinase inhibitors has been described (33 (link),34 (link)).